MicroRNA fingerprints during human megakaryocytopoiesis
Described herein is a method of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject.
1. A method of decreasing expression of a transcription factor gene product from the Maf family, also known as protooncogene c-Maf or V-maf musculoaponeurotic fibrosarcoma oncogene homolog, (MAFB in a subject having a cancer and/or myeloproliferative disorder associated with an overexpression of a MAFB gene product, comprising
administering an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof to the subject sufficient to decrease expression of the MAFB gene product in the subject, wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML).
2. The method of claim 1 , wherein the at least one miR-130a gene product or isolated variant or biologically-active fragment thereof comprises a nucleotide sequence that is complementary to a nucleotide sequence in the MAFB gene product.
3. The method of claim 1 , wherein the cancer and/or myeloproliferative disorder is a leukemia.
4. The method of claim 3 wherein the leukemia is acute myeloid leukemia.
5. The method of claim 4 , wherein the acute myeloid leukemia is acute megakaryoblastic leukemia.
6. The method of claim 1 , wherein the cancer is multiple myeloma.
7. The method of claim 1 , wherein the cancer and/or a myeloproliferative disorder is chronic myelogenous leukemia (CML).
8. The method of claim 1 , wherein the subject is a human.